Neurocrine Biosciences NBIX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $668.6M+119% | $478.6M+40.2% | $428M+10.9% | $348.3M+2.7% | $305.8M-17.3% | ||
| $26.6M+7.3% | $26M+10.6% | $25.8M+16.2% | $24.7M+16.5% | $24.8M+30.5% | ||
| $222.3M+9.1% | $217.9M+11.5% | $225.7M+35.0% | $213.5M+23.1% | $203.8M+2.5% | ||
| $118M+197% | $165.4M+234% | $85.9M— | -$117.3M— | -$121.2M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $248.9M+294% | $129.5M+60.5% | $67.4M+6.8% | ||
| $148.9M+152% | $160.2M+269% | $161M— | $149.4M— | $59M— | ||
| —— | —— | —— | —— | -$2.6M-162% | ||
| —— | —— | —— | —— | —— | ||
| $3.2M-13.5% | $4.1M+13.9% | $3.9M+11.4% | $3.8M+8.6% | $3.7M+5.7% | ||
| —— | —— | -$8.6M-38.7% | -$56.1M-90.8% | -$69.3M-349% | ||
| —— | —— | —— | —— | —— | ||
| $863.7M+63.0% | $782.7M+31.5% | $636.8M+33.7% | $567.3M+7.0% | $529.9M-17.9% | ||
| $34.8M-7.7% | $36.4M-4.7% | $43.7M+20.4% | $38.6M+7.8% | $37.7M+21.6% | ||
| $1.87B+84.9% | $1.32B+25.0% | $1.31B+6.3% | $1.13B-16.8% | $1.01B-32.4% | ||
| —— | —— | —— | —— | —— | ||
| -$784.8M— | -$264.4M— | -$279.8M— | —— | —— | ||
| —— | —— | —— | $467.7M— | $450M— | ||
| $120.9M+43.4% | $129.4M+6.0% | $102.1M-30.8% | $82.9M-40.7% | $84.3M-33.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$411.2M-143% | -$700.9M-652% | ||
| $72.4M+136% | $480M+2,752% | -$8.9M-116% | $124.3M+706% | -$202.2M— | ||
| $81.1M-62.8% | $81.4M-62.6% | $146.6M-23.2% | $197.2M+40.0% | $217.9M+323% | ||
| $9.4M-60.3% | $12.7M-51.5% | $16.3M-39.4% | $20.1M-23.9% | $23.7M+1.7% | ||
| $3.2M-13.5% | $4.1M+13.9% | $3.9M+11.4% | $3.8M+8.6% | $3.7M+5.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | $26.8M+158% | $22.7M+200% | $18.6M+292% | $14.5M+653% | ||
| $1.05B+6.2% | $1.09B+12.6% | $1.07B+6.5% | $1.11B+9.6% | $989.3M-5.3% | ||
| —— | —— | —— | —— | —— | ||
| $831.3M+68.9% | $748.7M+34.4% | $593.1M+34.8% | $528.7M+6.9% | $492.2M-19.9% | ||
| $831.3M+68.9% | $748.7M+34.4% | $593.1M+34.8% | $528.7M+6.9% | $492.2M-19.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Neurocrine Biosciences generate?
- Neurocrine Biosciences (NBIX) generated $863.7M in operating cash flow over the trailing twelve months.
- What is Neurocrine Biosciences's free cash flow?
- After $34.8M of capital expenditures, Neurocrine Biosciences's free cash flow was $831.3M over the trailing twelve months, up 68.9% year over year.
- Where does Neurocrine Biosciences's cash flow data come from?
- Every line is extracted from Neurocrine Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
